Systematic review / meta-analysis / 2021
Microbiota-driven therapy (prebiotics, probiotics, synbiotics) did not significantly reduce circulating TMAO or related metabolites in a meta-analysis of RCTs.
A systematic review and meta-analysis of 10 randomized controlled trials (12 arms, 342 patients) evaluated the effects of prebiotics, probiotics, or synbiotics compared to placebo on TMAO and related metabolites. Microbiota-driven therapy did not reduce circulating TMAO [SMD = -0.05, 95% CI (-0.36, 0.26), P = 0.749], choline [SMD = -0.34, 95% CI (-1.09, 0.41), P = 0.373], betaine aldehyde [SMD = -0.704, 95% CI (-1.789, 0.382), P = 0.204], or L-carnitine [SMD = -0.06, 95% CI (-0.38, 0.25), P = 0.692]. The authors noted that the conclusion needs future confirmation given the small sample size.
- Study type
- Systematic review and meta-analysis of RCTs
- Who was studied
- 342 patients (168 intervention, 174 control) across 10 studies (12 arms)
- What was measured
- Circulating TMAO, choline, betaine aldehyde, and L-carnitine levels
THE PAPER
Effects of Microbiota-Driven Therapy on Circulating Trimethylamine-N-Oxide Metabolism: A Systematic Review and Meta-Analysis.
Miao L, Du J, Chen Z, Shi D, Qu H. Front Cardiovasc Med, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.